OraSure Technologies, Inc. (NASDAQ:OSUR) updated its fourth quarter earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of $0.08-$0.09 for the period, compared to the Thomson Reuters consensus estimate of $0.08. The company issued revenue guidance of $45-$46 million, compared to the consensus revenue estimate of $39.66 million.

Several equities analysts have issued reports on the stock. Zacks Investment Research raised shares of OraSure Technologies from a hold rating to a buy rating and set a $23.00 price target on the stock in a report on Wednesday, October 25th. Jefferies Group LLC reaffirmed a buy rating and issued a $23.00 price target on shares of OraSure Technologies in a report on Friday, October 20th. Canaccord Genuity reaffirmed a buy rating and issued a $22.00 price target on shares of OraSure Technologies in a report on Tuesday, September 19th. Finally, BidaskClub lowered shares of OraSure Technologies from a buy rating to a hold rating in a report on Monday, July 31st. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. OraSure Technologies has an average rating of Buy and a consensus price target of $18.21.

OraSure Technologies (NASDAQ:OSUR) last announced its quarterly earnings data on Wednesday, August 2nd. The medical instruments supplier reported $0.09 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.07 by $0.02. OraSure Technologies had a net margin of 22.29% and a return on equity of 15.64%. The business had revenue of $40.18 million for the quarter, compared to analyst estimates of $36.54 million. During the same period last year, the business earned $0.07 EPS. The company’s revenue was up 28.1% on a year-over-year basis.

In other news, CFO Ronald H. Spair sold 510,112 shares of the firm’s stock in a transaction on Monday, August 7th. The shares were sold at an average price of $20.66, for a total value of $10,538,913.92. Following the sale, the chief financial officer now directly owns 208,606 shares in the company, valued at approximately $4,309,799.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Brian Smith sold 3,075 shares of the firm’s stock in a transaction on Tuesday, August 22nd. The shares were sold at an average price of $21.09, for a total transaction of $64,851.75. Following the completion of the sale, the insider now owns 24,540 shares in the company, valued at $517,548.60. The disclosure for this sale can be found here. Insiders sold a total of 717,601 shares of company stock worth $14,977,398 over the last 90 days. Company insiders own 6.40% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “OraSure Technologies, Inc. (OSUR) Releases Q4 Earnings Guidance” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/11/01/orasure-technologies-inc-osur-releases-q4-earnings-guidance.html.

OraSure Technologies Company Profile

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Earnings History and Estimates for OraSure Technologies (NASDAQ:OSUR)

Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.